玻璃体腔注射雷珠单抗对视网膜静脉阻塞眼部血流动力学的影响

doi:10.3969/j.issn.1674-490X.2020.06.006

摘要/Abstract

摘要： 目的探讨单眼玻璃体腔注射雷珠单抗治疗视网膜静脉阻塞短期内对眼球后血管血流动力学的影响。方法本研究为前瞻性介入性临床研究,纳入确诊为视网膜静脉阻塞继发黄斑水肿的患者,在玻璃体腔注射雷珠单抗前和注射后1周,应用彩色多普勒显像测量注射眼和对侧眼的眼动脉、视网膜中央动脉和睫状体后动脉的血流动力学参数,包括收缩峰值流速、舒张末期流速和阻力指数。结果玻璃体腔注射雷珠单抗显著降低了注射眼视网膜中央动脉和睫状后短动脉的收缩峰值流速和舒张末期流速,并显著提高了阻力指数(P<0.05)。注射后,注射眼与未注射眼在视网膜中央动脉和睫状后短动脉的收缩峰值流速、舒张末期流速和阻力指数上差异均有统计学意义(P<0.05)。结论玻璃体腔注射雷珠单抗会短时间内改变视网膜静脉阻塞继发黄斑水肿患者注射眼的眼部血流速度。

关键词: 雷珠单抗, 玻璃体腔注射, 视网膜静脉阻塞, 球后血流动力学

Abstract: Objective To investigate the short-term effect of single intravitreal ranibizumab injection on retrobulbar blood flow in patients with retinal vein occlusion. Methods In this prospective interventional study, patients with macular edema secondary to retinal vein occlusion were included. The hemodynamic parameters of the ophthalmic artery, central retinal artery and posteriorciliary artery comprising peak systolicvelocity, end-diastolic velocity, and resistive index were measured by using color doppler imaging in both injected and uninjected fellow eyes at baseline and one week after the injection. Results Intravitreal ranibizumab induced a significant reduction in the peak systolic velocity and end-diastolic velocity and a significant rise in the resistive index of the central retinal artery and short posterior ciliary artery of the injected eye. After injection, there was any significant difference between injected and uninjected eyes in the peak systolic velocity, end-diastolic velocity, and resistive index values of central retinal artery and short posterior ciliary artery. Conclusion In patients with macular edema secondary to retinal vein occlusion, intravitreal injection of ranibizumab alters retrobulbar blood flow velocities in injected eyes in the short-term period

Key words: ranibizumab, intravitreal injection, retinal vein occlusion, retrobulbar hemodynamics

中图分类号:

陈光,石荣兴,王旭凯,陈小平,彭新明. 玻璃体腔注射雷珠单抗对视网膜静脉阻塞眼部血流动力学的影响[J]. 医学研究与教育, 2020, 37(6): 35-41.

参考文献

[1] TAH V, ORLANS H O, HYER J, et al. Anti-VEGF therapy and the retina: an update[J]. J Ophthalmol, 2015, 2015: 1-13. DOI: 10.1155/2015/627674.
[2] ROGERS S, MCINTOSH R L, CHEUNG N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia[J]. Ophthalmology, 2010, 117(2): 313-319.e1. DOI: 10.1016/j.ophtha.2009.07.017.
[3] SHAHID H, HOSSAIN P, AMOAKU W M. The management of retinal vein occlusion: is interventional ophthalmology the way forward?[J]. Br J Ophthalmol, 2006, 90(5): 627-639. DOI: 10.1136/bjo.2005.068668.
[4] KOSS M J, PFISTER M, ROTHWEILER F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion[J]. Acta Ophthalmol, 2012, 90(2): e98-e103. DOI: 10.1111/j.1755-3768.2011.02292.x.
[5] SAWADA O, OHJI M. Retinal vein occlusion[J]. Dev Ophthalmol, 2016, 55: 147-153. DOI: 10.1159/000438971.
[6] CAMPOCHIARO P A, HEIER J S, FEINER L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study[J]. Ophthalmology, 2010, 117(6): 1102-1112. DOI: 10.1016/j.ophtha.2010.02.021.
[7] CAMPOCHIARO P A, BROWN D M, AWH C C, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study[J]. Ophthalmology, 2011, 118(10): 2041-2049. DOI: 10.1016/j.ophtha.2011.02.038.
[8] LASHAY A, RIAZI-ESFAHANI H, MIRGHORBANI M, et al. Intravitreal medications for retinal vein occlusion: systematic review and meta-analysis[J]. J Ophthalmic Vis Res, 2019, 14(3): 336-366. DOI: 10.18502/jovr.v14i3.4791.
[9] YOKOYAMA K, CHOSHI T, KIMOTO K, et al. Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular Glaucoma[J]. Acta Ophthalmol, 2008, 86(8): 927-928. DOI: 10.1111/j.1755-3768.2008.01187.x.
[10] ISOLA V, PECE A, MASSIRONI C, et al. Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients[J]. Clin Ophthalmol, 2013, 7: 455-460. DOI: 10.2147/OPTH.S30156.
[11] HOSSEINI H, RAZEGHINEJAD M R. Anterior ischemic optic neuropathy after intravitreal injection of bevacizumab[J].J Neuroophthalmol, 2009, 29(2):160-161. DOI: 10.1097/wno. 0b013e3181a5 8fd1.
[12] FURINO C, BOSCIA F, CARDASCIA N, et al. Hemorrhagic macular infarction after intravitreal bevacizumab for central retinal vein occlusion[J]. Ophthalmic Surg Lasers Imaging, 2010, 9: 1-2. DOI: 10.3928/15428877-20100215-57.
[13] DIMITROVA G, KATO S. Color Doppler imaging of retinal diseases[J]. Surv Ophthalmol, 2010, 55(3): 193-214. DOI: 10.1016/j.survophthal.2009.06.010.
[14] LI J, PAULUS Y M, SHUAI Y L, et al. New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion[J]. J Ophthalmol, 2017, 2017: 1-18. DOI: 10.1155/2017/4936924.
[15] MAGGIO E, METE M, MARAONE G, et al. Intravitreal injections for macular edema secondary to retinal vein occlusion: long-term functional and anatomic outcomes[J]. J Ophthalmol, 2020, 2020: 1-8. DOI: 10.1155/2020/7817542.
[16] CARRASCO J, PIETSCH G A, NICOLAS M P, et al. Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies[J]. Adv Ther, 2020, 37(1): 300-315. DOI: 10.1007/s12325-019-01147-6.
[17] BONNIN P, POURNARAS J A C, LAZRAK Z, et al. Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab(Avastin^®)in neovascular age-related macular degeneration[J]. Acta Ophthalmol, 2010, 88(6): 641-645. DOI: 10.1111/j.1755-3768.2009.01526.x.
[18] METE A, SAYGILI O, METE A, et al. Effects of intravitreal bevacizumab(Avastin)therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration[J]. J Clin Ultrasound, 2010, 38(2): 66-70. DOI: 10.1002/jcu.20650.
[19] PAPADOPOULOU D N, MENDRINOS E, MANGIORIS G, et al. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration[J]. Ophthalmology, 2009, 116(9): 1755-1761. DOI: 10.1016/j.ophtha.2009.03.017.
[20] MENDRINOS E, MANGIORIS G, PAPADOPOULOU D N, et al. Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration[J]. Acta Ophthalmol, 2013, 91(3): e184-e190. DOI: 10.1111/aos.12008.
[21] LIU M H, JIN H K, FLOTEN H S, et al. Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery[J]. Ann Thorac Surg, 2002, 73(3): 819-824. DOI: 10.1016/s0003-4975(01)03404-x.
[22] DONATI G, POURNARAS C J, MUNOZ J L, et al. Nitric oxide controls arteriolar tone in the Retina of the miniature pig[J]. Invest Ophthalmol Vis Sci, 1995, 36(11): 2228-2237.
[23] WEI W, CHEN Z W, YANG Q, et al. Vasorelaxation induced by vascular endothelial growth factor in the human internal mammary artery and radial artery[J]. Vasc Pharmacol, 2007, 46(4): 253-259. DOI: 10.1016/j.vph.2006.10.009.
[24] GOK M, KAPTI H B. Effect of intravitreal aflibercept(Eylea^®)on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration[J]. Int Ophthalmol, 2018, 38(2): 713-719. DOI: 10.1007/s10792-017-0522-6.
[25] AVERY R L, PEARLMAN J, PIERAMICI D J, et al. Intravitreal bevacizumab(avastin)in the treatment of proliferative diabetic retinopathy[J]. Ophthalmology, 2006, 113(10): 1695-1705.e6. DOI: 10.1016/j.ophtha.2006.05.064.
[26] AL-DHIBI H, KHAN A O. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema[J]. J Am Assoc Pediatr Ophthalmol Strabismus, 2009, 13(4): 400-402. DOI: 10.1016/j.jaapos.2009.03.006.
[27] HANHART J, TIOSANO L, AVERBUKH E, et al. Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema[J]. Eye, 2014, 28(6): 646-653. DOI: 10.1038/eye.2014.94.
[28] RAHIMY E, NYONGAND'O O, LENG T. Significant bilateral response in diabetic macular edema after single unilateral intravitreal aflibercept injection[J]. Ophthalmic Surg Lasers Imaging Retina, 2017, 48(2): 167-169. DOI: 10.3928/23258160-20170130-11.
[29] BAFFERT F, LE T, SENNINO B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling[J]. Am J Physiol Heart Circ Physiol, 2006, 290(2): H547-H559. DOI: 10.1152/ajpheart.00616.2005.
[30] MANCUSO M R, DAVIS R, NORBERG S M, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition[J]. J Clin Investig, 2006, 116(10): 2610-2621. DOI: 10.1172/jci24612.